Evicenter
Entyvio (vedolizumab) in Ulcerative colitis
Manufacturer
Takeda Pharmaceuticals U.S.A., Inc.
Prescribing information
Entyvio (opens in a new tab)
Questions
37
Last updated

All questions

Pharmacology: Entyvio (vedolizumab) in ulcerative colitis

1 question · 2 sources

Pharmacokinetics

Do the Entyvio Pen and Entyvio IV give similar drug levels?

Applies to Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

Note: Table 3 gives IV trough concentrations, including the every-8-week steady state at Week 46; the efficacy page compares the two routes by simulated average concentration at steady state. In the second passage the two trough values are, respectively, for ulcerative colitis (35.8 mcg/mL) and Crohn's disease (31.4 mcg/mL).